GLSI vs. GOSS, CAPR, TRVI, VERU, ALIM, ME, ACET, VACC, ATOS, and OGI
Should you be buying Greenwich LifeSciences stock or one of its competitors? The main competitors of Greenwich LifeSciences include Gossamer Bio (GOSS), Capricor Therapeutics (CAPR), Trevi Therapeutics (TRVI), Veru (VERU), Alimera Sciences (ALIM), 23andMe (ME), Adicet Bio (ACET), Vaccitech (VACC), Atossa Therapeutics (ATOS), and Organigram (OGI). These companies are all part of the "pharmaceutical preparations" industry.
Gossamer Bio (NASDAQ:GOSS) and Greenwich LifeSciences (NASDAQ:GLSI) are both small-cap medical companies, but which is the superior business? We will contrast the two companies based on the strength of their analyst recommendations, risk, profitability, earnings, community ranking, institutional ownership, valuation, media sentiment and dividends.
81.2% of Gossamer Bio shares are owned by institutional investors. Comparatively, 4.2% of Greenwich LifeSciences shares are owned by institutional investors. 9.5% of Gossamer Bio shares are owned by insiders. Comparatively, 52.9% of Greenwich LifeSciences shares are owned by insiders. Strong institutional ownership is an indication that endowments, hedge funds and large money managers believe a stock will outperform the market over the long term.
Gossamer Bio received 137 more outperform votes than Greenwich LifeSciences when rated by MarketBeat users. Likewise, 64.84% of users gave Gossamer Bio an outperform vote while only 33.33% of users gave Greenwich LifeSciences an outperform vote.
Greenwich LifeSciences is trading at a lower price-to-earnings ratio than Gossamer Bio, indicating that it is currently the more affordable of the two stocks.
Gossamer Bio's return on equity of -93.88% beat Greenwich LifeSciences' return on equity.
In the previous week, Greenwich LifeSciences had 1 more articles in the media than Gossamer Bio. MarketBeat recorded 1 mentions for Greenwich LifeSciences and 0 mentions for Gossamer Bio. Gossamer Bio's average media sentiment score of 0.69 beat Greenwich LifeSciences' score of 0.00 indicating that Greenwich LifeSciences is being referred to more favorably in the news media.
Gossamer Bio presently has a consensus target price of $7.65, suggesting a potential upside of 955.17%. Greenwich LifeSciences has a consensus target price of $36.00, suggesting a potential upside of 172.73%. Given Greenwich LifeSciences' higher possible upside, research analysts clearly believe Gossamer Bio is more favorable than Greenwich LifeSciences.
Gossamer Bio has a beta of 1.71, indicating that its stock price is 71% more volatile than the S&P 500. Comparatively, Greenwich LifeSciences has a beta of 1.37, indicating that its stock price is 37% more volatile than the S&P 500.
Summary
Gossamer Bio beats Greenwich LifeSciences on 8 of the 15 factors compared between the two stocks.
Get Greenwich LifeSciences News Delivered to You Automatically
Sign up to receive the latest news and ratings for GLSI and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the number of new MarketBeat users adding GLSI and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period.
This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
Greenwich LifeSciences Competitors List
Related Companies and Tools
